Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1371499 | 0.99 | SIRT6 (0.42) | SIRT6MAPTLMNAPOLBMAPK1 | |
| SCHEMBL4278090 | 0.92 | MAPT (0.41) | MAPTLMNAMAPK1ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4278084 | 0.91 | MAPT (0.41) | MAPTLMNAMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2678984 | 0.90 | SIRT6 (0.41) | SIRT6MAPTLMNAPOLBMAPK1 | |
| Hydrochloric Acid SCHEMBL2678981 | 0.90 | SIRT6 (0.40) | SIRT6MAPTLMNAPOLBMAPK1 | |
| SCHEMBL4291472 | 0.87 | FLT3 (0.40) | MAPTALDH1A1SMN1; SMN2WDR5 | |
| SCHEMBL1987021 | 0.87 | SIRT6 (0.42) | SIRT6MAPTLMNAPOLBMAPK1 | |
| Hydrochloric Acid SCHEMBL4291464 | 0.87 | FLT3 (0.40) | MAPTALDH1A1SMN1; SMN2WDR5 | |
| Hydrochloric Acid SCHEMBL1987018 | 0.86 | SIRT6 (0.41) | SIRT6MAPTLMNAPOLBMAPK1 | |
| SCHEMBL4701327 | 0.86 | MAPT (0.42) | MAPTLMNAPOLBALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| US-9012487-B2 | Bicyclo-pyrazoles active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-04-21 | — | — | US | disclosed |
| EP-1999131-B1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-10-23 | — | — | EP | disclosed |
| US-8461193-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-11 | — | — | US | disclosed |
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.I. (IT) | 2011-11-24 | — | — | US | disclosed |
| US-7968583-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-06-25 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2009-05-28 | — | — | US | disclosed |
| EP-1963326-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068637-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136513-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS | MAP3K19, CDK2, MAP3K1 | SIRT6 2677/4885MAPT 2911/4885LMNA 2859/4885 |
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | SIRT6 2172/4885MAPT 2209/4885LMNA 3860/4885 |
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | SIRT6 2172/4885MAPT 2209/4885LMNA 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.